Esperion appoints Ben Halladay as CFO, effective Nov 16, 2022

Esperion Therapeutics, Inc.

Ben Halladay appointed CFO effective Nov 16, 2022; previously Senior Director of FP&A at Esperion.
Annual base salary of $429,000; target annual bonus of 40% of base salary.
Reports to CEO Sheldon Koenig; prior roles at National Oilwell Varco, BMC Software, and Pfizer.
Holds CPA license; BA from Syracuse University and MBA from Fordham Gabelli School of Business.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Benjamin Halladay

Chief Financial Officer

ESPR · Esperion Therapeutics, Inc.

Effective: 2022-11-16
Filed: November 16, 2022, 6:59 PM ET

On November 16, 2022, the board of directors (the “Board”) of Esperion Therapeutics, Inc. (the “Company”) appointed Benjamin Halladay as the Company’s Chief Financial Officer pursuant to the terms of an employment agreement with Mr. Halladay (the “Halladay Agreement”), effective as of November 16, 2022 (the “Commencement Date”).

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Benjamin Halladay was appointed as Chief Financial Officer at Esperion Therapeutics, Inc..

Action: appointed
Role: Chief Financial Officer

Exact text from the filing

On November 16, 2022, the board of directors (the “Board”) of Esperion Therapeutics, Inc. (the “Company”) appointed Benjamin Halladay as the Company’s Chief Financial Officer pursuant to the terms of an employment agreement with Mr. Halladay (the “Halladay Agreement”), effective as of November 16, 2022 (the “Commencement Date”).

View on SEC.gov

Esperion Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-22-119533

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.